SCHEMBL14489129

SCHEMBL14489129

C[C@@H](CCCC(C)(C)O[Si](C)(C)C)[C@H]1CC[C@H]2C(=O)CCC[C@]12C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC25A P30304 2/20 0.47
▸ CDC25B P30305 1/20 0.47
▸ VDR P11473 12/20 0.46
▸ MAPT P10636 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ SREBF1 P36956 1/20 0.43
▸ NR1I2 O75469 1/20 0.42
▸ ABCB11 O95342 1/20 0.42
▸ GC P02774 1/20 0.42
▸ PGR P06401 1/20 0.42
▸ ADORA3 P0DMS8 1/20 0.42
▸ RXRA P19793 1/20 0.42
▸ CHRM3 P20309 1/20 0.42
▸ CNR1 P21554 1/20 0.42
▸ SLC6A2 P23975 1/20 0.42
▸ HTR2C P28335 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ AGTR1 P30556 1/20 0.42
▸ SLC6A4 P31645 1/20 0.42
▸ ADRA1A P35348 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4164697 1.00 CDC25A (0.47) CDC25ACDC25BVDRMAPTSMN1; SMN2
SCHEMBL14489088 1.00 CDC25A (0.47) CDC25ACDC25BVDRMAPTSMN1; SMN2
SCHEMBL28733909 1.00 CDC25A (0.47) CDC25ACDC25BVDRMAPTSMN1; SMN2
SCHEMBL8093383 0.95 CDC25A (0.42) CDC25ACDC25BVDRMAPTSMN1; SMN2
SCHEMBL8527156 0.95 CDC25A (0.42) CDC25ACDC25BVDRMAPTSMN1; SMN2
SCHEMBL14112463 0.92 CDC25A (0.46) CDC25ACDC25BVDRMAPTSMN1; SMN2
SCHEMBL3220674 0.90 CDC25A (0.37) CDC25ACDC25BVDRMAPTSMN1; SMN2
SCHEMBL13392704 0.90 CDC25A (0.37) CDC25ACDC25BVDRMAPTSMN1; SMN2
SCHEMBL7615044 0.90 CDC25A (0.37) CDC25ACDC25BVDRMAPTSMN1; SMN2
SCHEMBL24286115 0.90 CDC25A (0.46) CDC25ACDC25BVDRMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9221753-B2 Process for the synthesis of vitamin D compounds and intermediates for the synthesis of the compounds CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-12-29 — — US disclosed
US-20070135394-A1 Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-06-14 — — US disclosed
US-20070135394-A1 Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135394-A1 Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds CYP24A1, CYP2R1, VDR CDC25A 2284/4885CDC25B 1816/4885VDR 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback